THE REPORTED SUCCESSFUL BABY DELIVERY AFTER PREIMPLANTATION GENETIC TESTING FOR ANEUPLOIDIES (PGT-A) BY MEANS OF NEXT GENERATION SEQUENCING (NGS).

N. Nigmatova MMedSci¹,*, B. Abdilmanova MD¹, V. Schigolev MD, PhD²

¹Genom-Astana Fertility Center
Nur-Sultan, Kazakhstan
²Genom
Moscow, Russia

ANNOTATION

The aim of this case report is to demonstrate a successful delivery of a baby after transfer of a blastocyst tested for aneuploidies by means of NGS. A woman aged 35 having two miscarriages decided for ICSI program with PGT-A analysis. Six eggs were fertilized out of 9 metaphase II oocytes. Five good quality blastocysts were submitted for genetic screening using 24-chromosome next generation sequencing (NGS). Two blastocysts were diagnosed as euploid and recommended for transfer. One euploid blastocyst was thawed and transferred to the patient’s uterus lining. Successful pregnancy was confirmed at 7 weeks of gestation with heartbeat. Successful delivery was achieved by Caesarean section at 38-39 weeks of gestation. Karyotyping demonstrated healthy genetic constitution of a baby. This case demonstrates a good evidence and potential of a transport scheme collaboration between IVF and genetic laboratories.

Key words: ART; IVF; NGS; PGT-A; TE (trophectoderm).

INTRODUCTION

Chromosomal aberrations are the most frequent etiology for early pregnancy losses in the first trimester and covers 50% of spontaneous abortions [1,2]. Preimplantation genetic testing for aneuploidies (PGT-A), previously known as preimplantation genetic screening (PGS), was developed to prevent early miscarriages at embryonic stage in conjunction with IVF [3].

Nowadays, good quality laboratory is the one offering PGT service. A variety of genetic platforms exists for screening of chromosomal aberrations. Fluorescence in situ hybridization (FISH) analysis, first clinical case published in 1993 [4], as a method is fading gradually. Such limitation, as analysis of 5 or 9 chromosomes is not satisfying anymore considering that chromosome or chromatid missegregation may occur at any chromosome set and lead to genetic malformations [5]. Array comparative genomic hybridization (array CGH) and next generation sequencing (NGS), both allow comprehensive screening of 23 pairs of chromosomes [6].

In order to detect 20% of mosaicism within an embryo by NGS, at least 5 TE cells should be biopsied [10]. Therefore, majority of laboratories moving from blastomere biopsy to trophoderm (TE) biopsy since several cells could be taken for genetic analysis. On average, 5 – 10 cells are recommended for analysis [10], which will provide a more strong and valid genetic result. Resolution, quality and mosaicism detection by NGS for embryo screening seems to be higher [6-9]. Embryos tested by NGS might have stronger chance for successful pregnancy and lower risk for the pregnancy loss [6,8]. Meantime, higher sensitivity for mosaicism assumes less euploid embryos, which demonstrates a risk of overdiagnosis the euploid embryos as mosaic. In all cases, both platforms are eligible and successfully applied worldwide.

However, only large scale IVF centers can afford the expense of equipment and software, the strong skills and knowledge of professionals including analysis and interpretation of bioinformatics data [11]. The transport scheme sounds feasible for small and average scale laboratories.

Here, we report a successful pregnancy and delivery of a genetically healthy baby after PGT-A by means of NGS collaborating with the genetic laboratory on transport scheme. In our report, we use PGT related terminology according to the ICMART and ASRM international glossary on infertility and fertility [3].

CASE REPORT

INFERTILITY HISTORY

A couple with an infertility history of more than 5 years. At the moment of the treatment (October 2017), the female patient was 35 years old and was diagnosed with secondary infertility, pelvic pain during irregular menses, adenomyosis and polymorphism for thrombophilia. For the latter she was prescribed medication by hematologist. The husband was 51 years old; semen analysis was analyzed in accordance with WHO Lab manual [12] and showed normozoosperma. The couple has two children conceived naturally and born in 2003
Eleven cumulus-oocyte complexes (COC) were aspirated recombinant human chorionic gonadotropin (rhCG; 250 mg added to the treatment. After 9 days of ovarian stimulation, 0.25 mg of antagonist (Orgalutran; Merck Serono) was added to the treatment. After 9 days of ovarian stimulation, recombinant human choriionic gonadotropin (rhCG; 250 mg of Ovitrelle; Merck Serono) as a trigger was administered. Eleven cumulus-oocyte complexes (COC) were aspirated under ultrasound, 37 hours after rhCG injection.

CONTROLLED OVARIAN STIMULATION
On day 3, female patient’s blood testing demonstrated FSH = 7.1 IU/ml, LH = 5.2 IU/ml, Testosterone = 0.22 nmole/L, AMH = 5.38 ng/ml.

From day 3 of menstruation, the female patient was prescribed with 150/75 IU of recombinant FSH and LH (Pergoveris; Merck Serono), 75 IU of recombinant FSH (Gonal F; Merck Serono). From the 6th day of stimulation 0.25 mg of antagonist (Orgalutran; Merck Serono) was added to the treatment. After 9 days of ovarian stimulation, recombinant human choriionic gonadotropin (rhCG; 250 mg of Ovitrelle; Merck Serono) as a trigger was administered. Eleven cumulus-oocyte complexes (COC) were aspirated in the morning and hatching blastocyst was transferred in culture medium Sage HSA at 1 pm. At the day of transfer, endometrium thickness was 11.5 mm.

OUTCOMES
Clinical pregnancy was confirmed at 7 weeks of gestation with a heartbeat. A healthy baby was born. The karyotyping of a baby demonstrated no presence of chromosomal aberrations.

DISCUSSION
The prevalent method for PGT was FISH analysis for decades worldwide. FISH analysis seems to be the cheapest amongst the methods, although it encounters well-known limitations like a limited number of chromosomes to be analyzed, availability of the cytogenetic laboratory, labor-intensive work [17].

Array CGH for preimplantation genetic analysis is a good tool. It was successfully implemented for all the stages of biopsy including randomized controlled trial and retrospective case-control studies [23]. It was demonstrated that NGS results 100% correlate with array CGH results for aneuploidy [18-19]. However, NGS protocols provide enhanced detection of segmental aneuploidies and detect mosaicism from 20% [8,19]. Meantime, array CGH detects 40-60% mosaicism [8]. Therefore, higher resolution of NGS allows less mistakes and a positive impact on the clinical outcome decreasing the miscarriage rate.

The clinical implementation of NGS into the laboratory lies in patients’ strong wish to have a healthy child and staff’s determination to offer the best possible in IVF market. Moreover, it is pivotal in competitive environment to offer a range of services: aneuploidy screening, genetic testing for monogenic diseases (PGT-M), for structural rearrangements (PGT-SR) and Rhesus factor of an embryo alone and along with comprehensive chromosome screening. Implementation of a genetic unit into the fertility clinic is not affordable for majority of IVF units. Therefore, the transport scheme seems a viable option for small and average size IVF units. Therefore, the transport scheme lies in patients’ strong wish to have a healthy child and staff’s determination to offer the best possible in IVF market.

The clinical implementation of NGS into the laboratory lies in patients’ strong wish to have a healthy child and staff’s determination to offer the best possible in IVF market. Moreover, it is pivotal in competitive environment to offer a range of services: aneuploidy screening, genetic testing for monogenic diseases (PGT-M), for structural rearrangements (PGT-SR) and Rhesus factor of an embryo alone and along with comprehensive chromosome screening. Implementation of a genetic unit into the fertility clinic is not affordable for majority of IVF units. Therefore, the transport scheme seems a viable option for small and average size IVF units, considering that successful biopsy rate is 98.2% in our clinic, which is acceptable according to the ESHRE Vienna consensus (ESHRE SIG of Embryology, 2017) [20].

The PGT also demonstrates indirect benefits. One of them is to reduce amount of embryos to store. The non-recommended ones are being discarded upon informed consent from the patient. The embryos with detected mosaicism is a subject of debate inquiring extensive genetic counseling, but final decision should be up to the patients.

Futhermore, PGT is a good mean to reduce amount of transferred embryos since only one blastocyst is vitrified per straw. Multiple pregnancies are still a milestone that demands a solution and are associated with elevated risks of obstetric complications [21]. Up to date, in Kazakhstan, three embryos are allowed for intrauterine transfer [22]. However, the maximum to be transferred is, predominantly, one or two as a policy of the majority (personal communication). Therefore, in order to reduce the number of embryos for transfer, especially, in advanced maternal age group, PGT implementation might assist in that by choosing a single genetically “healthy” embryo [21].

The above clinical case demonstrates the efficiency of clinical implementation of NGS on the transport scheme.
Nowadays, collaborating with large genetics laboratories with well-established logistics the IVF center of any size can afford PGT service to the patients. However, it is crucial to choose the lab based not only on the quality of services, but also its variety.

Declaration: The authors report no financial or commercial conflicts of interest.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

REFERENCES

[1] Hassold T, Chen N, Funkhouser J, Jooss T, Manuel B, Matsuura J et al. A cytogenetic study of 1000 spontaneous abortions. Ann Hum Genet 1980; 44: 151-78. DOI: 10.1111/j.1469-1809.1980.tb00955.x
[2] Petracci F, Colaci DS, Igarzabal L, Gadow E. Cytogenetic analysis of first trimester pregnancy loss. Int J Gynaecol Obstet 2009; 104: 243-44. doi: 10.1016/j.ijgo.2008.10.014.
[3] Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, De Mouzon J, Sokol R et al. The international glossary on infertility and fertility care. Fertil Steril 2017; 108(3): 0015-0282. https://dx.doi.org/10.1016/j.fertnstert.2017.06.005
[4] Delhanty JD, Griffin DK, Handyside AH, Harper J, Atkinson GH, Pieters MH et al. Detection of aneuploidy and chromosomal mosaicism in human embryos during preimplantation sex determination by fluorescent in situ hybridization (FISH). Hum Mol Genet 1993; 2(8): 1183-85. DOI: 10.1093/hmg/2.8.1183
[5] Munné S, Magli C, Bahce M, Fung J, Legator M, Morrison L. Preimplantation diagnosis of the aneuploidies most commonly found in spontaneous abortions and live births: XY, 13, 14, 15, 16, 18, 21, 22. Prenat Diagn. 1998; 18(13): 1459-66. DOI: 10.1002/(sici)1097-0223(199812)18:13<1459::aid-pd514>3.0.co;2-v
[6] Yang Z, Lin J, Zhang J, Fong WI, Li P, Zhao R. Randomized comparison of next-generation sequencing and array comparative genomic hybridization for preimplantation genetic screening: a pilot study. BMC Med Genom 2015; 8: 30. https://doi.org/10.1186/s12920-015-0110-4
[7] Fiorentino F, Bircik A, Bono S, Spizzichino L, Cotroneo E, Cottone G et al. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertil Steril 2014; 101: 1375-82. DOI: 10.1016/j.fertnstert.2014.01.051
[8] Friedenthal J, Maxwell S, Munné S, Kramer Y, McCaffrey C et al. Next generation sequencing for preimplantation genetic screening improves pregnancy outcomes compared with array comparative genomic hybridization in single thawed euploid embryo transfer cycles. Fertil Steril 2018; 109(4): 627-32. DOI: 10.1016/j.fertnstert.2017.12.017
[9] Munné S, Wells D. Detection of mosaicism at blastocyst stage with the use of high-resolution next-generation sequencing. Fertil Steril 2017; 107: 1085-91. DOI: 10.1016/j.fertnstert.2017.03.024
[10] Munné S, Blazek J, Large M, Martinez-Ortiz PA, Niesson H, Liu E. Detailed investigation into the cytogenetic constitution and pregnancy outcome of replacing mosaic blastocysts detected with the use of high-resolution next-generation sequencing. Fertil Steril 2017; 108: 62-71.e8. DOI: 10.1016/j.fertnstert.2017.05.002
[11] Aleksandrova NV, Shubina ES, Ekimov AN, Kodyleva TA, Mukosey IS, Makarova NP et al. Comparative results of preimplantation genetic screening by array comparative genomic hybridization and new-generation sequencing. Mol Biol 2017; 51(2): 269-73. DOI: 10.7868/S0026898417010025
[12] World health organization (WHO) laboratory manual for the examination and processing of human semen. 5th edition. 2010. ISBN: 978 92 4 154778 9
[13] Scott L, Alvero R, Leondires M, Miller B. The morphology of human pronuclear embryos is positively related to blastocyst development and implantation. Hum. Reprod. 2000; 15: 2394-403. DOI: 10.1093/humrep/15.11.2394
[14] Gardner DK, Schoolcraft WB. In vitro culture of human blastocysts. In Jansen, R. and Mortimer, D. (eds). Toward Reproductive Certainty: Fertility and Genetics Beyond 1999. London: Parthenon Publishing; 1999a, p. 378-388.
[15] Gardner DK, Schoolcraft WB. Culture and transfer of human blastocysts. Curr Opin Obstet Gynecol 1999b; 11: 307-331. DOI: 10.1097/00001703-199906000-00013
[16] Kuwayama M. Highly efficient vitrification for cryopreservation of human oocytes and embryos: the Cryotop method. Theriogenol 2007; 67(1): 73-80. DOI: 10.1016/j.theriogenology.2006.09.014
[17] Maalouf W. Setting up PGD lab. In: Varghese AC, Sjoblom P, Jayaprakasan K, editors. A practical guide to setting up an IVF Lab, embryo culture systems and running the unit. Jaypee Brothers Medical Publishers Pvt Ltd; 2013, Ch. 6, p. 61-68. ISBN 978-93-5090-516-6.
[18] Kung A, Munné S, Bankowski B, Coates A, Wells D. Validation of next-generation sequencing for comprehensive chromosome screening of embryos. Reprod Biomed Online 2015; 31: 760-69. DOI: 10.1016/j.rbmo.2015.09.002
[19] Handyside AH. 24-chromosome copy number analysis: a comparison of available technologies. Fertil Steril 2013; 100: 595-602. DOI: 10.1016/j.fertnstert.2013.07.1965
[20] ESHRE Special Interest Group of Embryology and Alpha Scientists in reproductive Medicine. 2017. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod. Biomed. Online. https://doi.org/10.1016/j.rbmo.2017.06.015
[21] Ubaldi FM, Capalbo A, Colamaria S, Ferrero S, Maggiulli R, Vajta G. Reduction of multiple pregnancies in the advanced maternal age population after implementation of an elective single embryo transfer policy coupled with enhanced embryo...
ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ ПО ИСПОЛЬЗОВАНИЮ СЕКВЕНИРОВАНИЯ НОВОГО ПОКОЛЕНИЯ (NGS) В ЦЕЛЯХ ПРОВЕДЕНИЯ ПРЕИМПЛАНТАЦИОННОГО ГЕНЕТИЧЕСКОГО ТЕСТИРОВАНИЯ НА АНЕУПЛОИДИИ (ПГТ-А)

Н.П. Нигматова MMedsC*, Б.Ж. Абдильманова MD1, В.Н. Щиголев MD, PhD2

1Клиника репродукции человека «Геном-Астана»
Казахстан, Нур-Султан
2Центральный офис сети «Геном»
Россия, Москва

Описание клинического случая демонстрирует успешное завершение программы ЭКО рождением ребенка используя преимплантационное генетические тестирование (ПГТ) методом NGS (секвенирование нового поколения). Пациентка в возрасте 35 лет с наличием двух замерших беременностей обратилась в клинику. Оплодотворение проведено методом ИКСИ, 6 из 9 зрелых яйцеклеток оплодотворились. Пять бластоцист хорошего качества и выше отправлены на генетический анализ методом NGS. Две бластоцисты диагностированы зуплонидными и рекомендованы к переносу. Одна бластоциста разморожена и перенесена. Беременность завершилась родами на 38-39 неделе кесаревым сечением. Картитирование выявило здоровый генетический набор хромосом у ребенка (девочки). Данный клинический случай демонстрирует, что транспортная схема является отличной альтернативной сотрудничества между генетическими и ЭКО лабораториями.

Ключевые слова: BPT; IVF; NGS; ПГТ-А; TE (трофэктодерма)

ТУЙНДЕМЕ
АНЕУПЛОИДИЯ (PGT-A) УШІН ТРЕТІЛЬЕУ УШІН КЕЛЕСІ БУЫННЫҢ РЕТТЕЛІГІН (NGS) ҚОЛДАНАУДЫҢ КЛИНИКАЛЫҚ ЖАҒДАЙЫНЫҢ СИПАТТАМАСЫ

Н.П. Нигматова MMedsC*, Б.Ж. Абдильманова MD1, В.Н. Щиголев MD, PhD2

1«Геном-Астана» Адам ұрпағын өрбіту Клиникасы
Қазақстан, Нұр-Сұлтан.
2«Геном» - клиникалар желісі
Ресей, Москва.

Клиникалық жағдайларды сипаттау барысында ЭКУ бағдарламасы бойынша имплантация алдына эмбрионға жұрғізілген генетикалық тасдауы (ПГТ) NGS (жана буынды сиквинирлеу) әдісін колдануда бала туылуының сәтті аяқталуының қорсетті. Клиника комегіне 35 әшірет әрі жұктырылған және жетілген бластиоцисттардың бірінен әсір жатқылыққа аяқталғандығына жатады. Үркінді және 38-39 аптада қарынды жарып алу әдісінен әсір жатқылыққа аяқталды. Баланың (қыз бала) қаріптіктік талдауға бойынша генетикалық хромосом сәтті аяқталуына жатады. Бала әсірінің жатқылған жағынаға екі бластоцисттар туралы қарап алды. Осы клиникалық жағдайлар қоңғырау жүргіздігіне тәуекелді. Осы клиникалық жағдай транспорттың жүйе бойынша генетикалық телесін ЭКУ зертханаларын әрекеттігі жақсы жақсы бала ма екендігін көрсетеді.

Түйін сөздер: ART; IVF; NGS; ПГТ-А; TE (трофэктомодерма).